Adrian Jubb

Adrian Jubb, MD PhD has a diverse and extensive work experience in the medical and pharmaceutical field. Adrian currently holds the position of Executive Vice President, Head of Clinical Development at Zentalis Pharmaceuticals. Prior to this, they served as the Senior Vice President of Clinical Development at the same company. Adrian has also been a part of the Scientific Advisory Board at Biotheryx, Inc. and served as a FAST Advisor at California Life Sciences (CLS). Adrian Jubb has their own consulting firm, AJ Clinical Development Consulting LLC, where they work as a Principal.

Earlier in their career, Adrian Jubb held the position of Chief Medical Officer at Flare Therapeutics. Adrian was also the Head of Clinical Oncology and Neurology at 23andMe, where they led the research and development of treatments for various diseases. Before that, they served as the Chief Medical Officer and Senior Vice President at Immune-Onc Therapeutics.

Adrian Jubb has held various positions at Achaogen, including Vice President, Head of Early Development, Senior Medical Director & Head of Early Development, and Medical Director. Adrian has also worked at Genentech as a Medical Director and Pathologist & Scientist.

Adrian started their career at the University of Oxford, where they held the positions of Academic Clinical Lecturer and Resident and Research Fellow.

Overall, Adrian Jubb's work experience showcases their expertise in clinical development, medical research, and leadership roles in the pharmaceutical industry.

Dr. Adrian Jubb obtained their MBChB (Hons) degree in Medicine from the University of Leeds in 2007. Prior to that, they completed a PhD in Medicine at the same university in 2005. Adrian also holds a BSc (Hons) degree in Clinical Sciences from the University of Leeds, which they earned in 2001. Dr. Jubb is a member of the Royal College of Pathologists, having obtained their FRCPath degree in 2013. Adrian completed their secondary education at Stockport Grammar School.